SwanBio is now part of Spur Therapeutics.

Our potential first-in-class gene therapy candidate for adrenomyeloneuropathy (AMN) has joined Spur’s expanding pipeline of next-generation genetic medicines. Learn more and get updates at SpurTherapeutics.com.

This site will remain live until Q4 2024 as we transition content to our new site.

Events & Presentations

American Academy of Neurology 2023 Annual Meeting | April 22-27, 2023

European Academy of Neurology 8th Annual Congress | June 25 – 28, 2022

Investor
Inquiries

Jan Case
investors@swanbiotx.com

 

Media
Queries

Lara Furst
703-946-0183
media@swanbiotx.com